About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 300 record(s)
Req # ACA-2020-00679
Provide documents showing evidence of plans and efforts to reach out to Indigenous people to participate in each of the Accessibility Standards Canada technical committees.Organization: Accessibility Standards Canada
September 2020
Req # A-2020-00004
List of mandatory or voluntary training, info sessions, awareness sessions, and sensitivity training from January 1, 2020 to September 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-04135
Copies of the Human Drug Advisory (HDAP) report for erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
September 2020
Req # A-2020-09098
Copies of all records discussing the impacts of the regulatory changes to the PMPRB from August 2019 until August 2020. Copies of all correspondence from all pharmaceutical companies expressing their concerns with the changes and any responses back to these companies. Copies of all correspondence from all advocating groups expressing concerns with the changes and any responses back to these groups. Copies of all correspondence between departmental staff discussing the impacts of the regulatory changes to the PMPRB. Copies of all records discussing the impacts of the PMPRB changes on individuals living with rare diseases. Copies of all correspondence from Vertex Pharmaceuticals relating to Kalydeco, Orkambi, Symdeko, and Trikafta. Copies of all correspondence between government officials (Prime Minister, Ministers, all members of parliament, constituency staff, deputies, assistant deputies, directors, managers, supervisors, staff, and any other employee of the Government of Canada relating to the PMPRB regulatory changes. Copies of all presentations relating to the PMPRB regulatory changes.Organization: Patented Medicine Prices Review Board Canada
September 2020
Nothing to report this month
Organization: Sustainable Development Technology Canada
Req # ACA-2020-00255
1. Technical Committee_Plain Language_EN, 2. Technical Committee_Plain Language_FR, 3. Technical Committee_Employment_FR, 4. Final Draft – Standards Development Technical Committees – Employment, 5. Final Draft – Standards Development Technical Committees –plain language.Organization: Accessibility Standards Canada
August 2020
Req # ACA-2020-00533
Provide documentary evidence that members of the Technical Committee responsible for standards development for outdoor spaces have: a) been advised to reach out to Parks Canada to participate in the development of outdoor spaces, b) been directed to reach out to Parks Canada to participate in the development of outdoor space, c) have reached out to Parks Canada to participate in the development of outdoor space.Organization: Accessibility Standards Canada
August 2020
Req # ACA-2020-00534
Send all documents that provide objective evidence of the various types of designs of washrooms that have been considered to ensure that Accessibility Standards Canada/Canadian Accessibility Standards Development Organization employees with disabilities or people with disabilities who visit the buildings do not face significant obstacles that disadvantage them.Organization: Accessibility Standards Canada
August 2020
Req # A-2020-01436
Copies of reports, discussions, briefings, memos and decisions related to the introductory price review for erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
August 2020
Req # A-2020-04137
Copies of the PMPRB documentation related to the scientific review and pricing review of erenumab (Aimovig) from January 2018 to February 2020.Organization: Patented Medicine Prices Review Board Canada
August 2020